A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment

Nerissa George, AnnMarie Liapakis, Kevin M Korenblat, Tingting Li, David Roth, Jerry Yee, Kevin J Fowler, Lehman Howard, Jingxia Liu, Mary C Politi, Nerissa George, AnnMarie Liapakis, Kevin M Korenblat, Tingting Li, David Roth, Jerry Yee, Kevin J Fowler, Lehman Howard, Jingxia Liu, Mary C Politi

Abstract

Rationale & objective: Patient education and decision support tools could facilitate decisions around the timing of antiviral therapy in patients living with both hepatitis C virus (HCV) infection and chronic kidney disease (CKD). We previously developed a tool through the HELP (Helping Empower Liver and Kidney Patients) study. This article evaluates the preliminary efficacy and usability of the tool among participants with both HCV infection and CKD.

Study design: Pre-post study pilot evaluation.

Setting & participants: Participants were at least 18 years old, were English speaking, and had a diagnosis of chronic HCV infection and CKD; they were seen in CKD clinics, dialysis units, and/or hepatology and liver transplantation clinics.

Intervention: Electronic patient decision support tool.

Outcomes: Participants' change in knowledge, certainty about choice, decision self-efficacy, patients' treatment preferences, and tool usability.

Results: 70 participants were recruited; 56 of 70 (80.0%) completed study procedures. Nearly all (51/56; 91.1%) requested paper-based study procedures despite the electronic design of the tool. Participants reported that they were most worried about the following treatment factors: (1) cost of drugs to treat HCV infection, (2) how their HCV infection affected their CKD, and (3) wait times for a kidney transplant. After using the decision tool, participants had significantly higher HCV infection and CKD knowledge (mean posttest percent of questions answered correctly = 65.74% vs pretest percent of questions answered correctly = 53.44%; P < 0.001) and more certainty about choice (mean posttest = 3.13 vs pretest = 2.65; P = 0.05). There were no significant changes in decision self-efficacy (mean posttest = 86.62 vs pretest = 84.68; P = 0.48).

Limitations: Single-site pilot study to explore preliminary tool efficacy and usability.

Conclusions: This study suggests that a decision tool may support informed patient-centered choices among patients with HCV infection and CKD. Future studies should evaluate ways to improve care decisions in a larger sample using both paper-based and electronic materials.

Funding: Merck & Co, Inc, Kenilworth, NJ.

Trial registration: Registered at clinicaltrials.gov with study number NCT03426787.

Keywords: chronic kidney disease; decision aid; decision support; hepatitis C virus; patient education.

© 2019 The Authors.

Figures

Graphical abstract
Graphical abstract

References

    1. Centers for Disease Control and Prevention Hepatitis C FAQs for health professionals.
    1. Zibbell J.E., Asher A.K., Patel R.C. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–181.
    1. Fabrizi F., Martin P., Dixit V. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7(4):549–557.
    1. Park H., Chen C., Wang W. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018;67(2):492–504.
    1. Butt A.A., Wang X., Fried L.F. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57(3):396–402.
    1. Fabrizi F., Dixit V., Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19(9):601–607.
    1. Goodkin D.A., Bieber B., Jadoul M. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12(2):287–297.
    1. Noureddine L.A., Usman S.A., Yu Z. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol. 2010;32(4):311–316.
    1. Fabrizi F., Martin P., Dixit V. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5(6):1452–1461.
    1. Terrault N.A., Adey D.B. The kidney transplant recipient with hepatitis C infection: pre-and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2(3):563–575.
    1. Afsar B., Elsurer R., Sezer S. Quality of life in hemodialysis patients: hepatitis C virus infection makes sense. Int Urol Nephrol. 2009;41(4):1011–1019.
    1. Azmi A.N., Tan S.-S., Mohamed R. Hepatitis C and kidney disease: an overview and approach to management. World J Hepatol. 2015;7(1):78–92.
    1. Feeney E.R., Chung R.T. Antiviral treatment of hepatitis C. BMJ. 2014;349:g3308.
    1. Roth D., Nelson D.R., Bruchfeld A. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–1545.
    1. Gane E., Lawitz E., Pugatch D. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448–1455.
    1. Goodkin D.A., Bieber B., Gillespie B. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38(5):405–412.
    1. Hart A., Smith J.M., Skeans M.A. OPTN/SRTR 2016 Annual Data Report: kidney. Am J Transplant. 2018;18(suppl 1):18–113.
    1. Bhamidimarri K.R., Ladino M., Pedraza F. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. Transpl Int. 2017;30(9):865–873.
    1. Kalantar-Zadeh K., Kilpatrick R.D., McAllister C.J. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18(5):1584–1593.
    1. Czyżewski L., Sańko-Resmer J., Wyzgał J. Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. Ann Transplant. 2014;19:576–585.
    1. Wang S.-M., Liu J.H., Chou C.-Y. Mortality in hepatitis C-positive patients treated with peritoneal dialysis. Perit Dial Int. 2008;28(2):183–187.
    1. Goldberg D.S., Reese P.P. New insights into optimal timing of hepatitis C virus treatment for dialysis patients waitlisted for kidney transplant. Ann Intern Med. 2018;169(4):256–257.
    1. Millman A.J., Ntiri-Reid M.B., Irvin R. Barriers to treatment access for chronic hepatitis C virus infection: a case series. Top Antivir Med. 2017;25(3):110–113.
    1. Ladino M., Roth D. Clinical trials: treatment of HCV-infected patients with advanced kidney disease. Nat Rev Nephrol. 2018;14(1):6–8.
    1. Dejman A., Ladino M.A., Roth D. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodial Int. 2018;22(suppl):S36–S44.
    1. Politi M.C., George N., Li T. Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease. Pilot Feasibility Studies. 2018;4:55.
    1. O'Connor A.M. Validation of a decisional conflict scale. Med Decis Mak. 1995;15(1):25–30.
    1. O’Connor A. User Manual-Decision Self-efficacy Scale. Patient Decision Aids, Ottawa Hospital Research Institute (OHIR) website. 1995.
    1. Brooke J. Digital Equipment Co Ltd; Reading, UK: 1986. System Usability Scale (SUS): A Quick-and-Dirty Method of System Evaluation User Information; p. 43.
    1. Morris N.S., MacLean C.D., Chew L.D. The Single Item Literacy Screener: evaluation of a brief instrument to identify limited reading ability. BMC Fam Pract. 2006;7:21.
    1. Degner L.F., Sloan J.A., Venkatesh P. The control preferences scale. Can J Nurs Res Arch. 1997;29(3):21–43.
    1. Souza J.A., Yap B.J., Wroblewski K. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST) Cancer. 2017;123(3):476–484.
    1. Goutzamanis S., Doyle J.S., Thompson A. Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study. BMC Infect Dis. 2018;18(1):151.
    1. Pathak S., George N., Monti D. Evaluating adaptation of a cancer clinical trial decision aid for rural cancer patients: a mixed-methods approach. J Cancer Educ. 2018 doi: 10.1007/s13187-018-1377-x.
    1. US Food & Drug Administration 2017 Drug Trials Snapshots Summary Report. 2017.
    1. Byrne M.M., Tannenbaum S.L., Glück S. Participation in cancer clinical trials:why are patients not participating? Med Decis Mak. 2014;34(1):116–126.
    1. Politi M.C., Kuzemchak M.D., Kaphingst K.A. Decision aids can support cancer clinical trials decisions: results of a randomized trial. Oncologist. 2016;21(12):1461–1470.
    1. Stewart B.J., Mikocka-Walus A.A., Harley H. Help-seeking and coping with the psychosocial burden of chronic hepatitis C: a qualitative study of patient, hepatologist, and counsellor perspectives. Int J Nurs Stud. 2012;49(5):560–569.
    1. Wachterman M.W., McCarthy E.P., Marcantonio E.R. Mistrust, misperceptions, and miscommunication: a qualitative study of preferences about kidney transplantation among African Americans. Transplant Proc. 2015;47(2):240–246.
    1. Sheu J., Ephraim P.L., Powe N.R. African American and non-African American patients’ and families’ decision making about renal replacement therapies. Qual Health Res. 2012;22(7):997–1006.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever